These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37953483)

  • 1. Quantifying the Disadvantage of Small Recipient Size on the Liver Transplantation Waitlist, a Longitudinal Analysis Within the Eurotransplant Region.
    Sneiders D; van Dijk ARM; Darwish-Murad S; van Rosmalen M; Erler NS; IJzermans JNM; Polak WG; Hartog H;
    Transplantation; 2024 May; 108(5):1149-1156. PubMed ID: 37953483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk Factors for High Mortality on the Liver Transplant Waiting List in Times of Organ Shortage: A Single-Center Analysis.
    Husen P; Hornung J; Benko T; Klein C; Willuweit K; Buechter M; Saner FH; Paul A; Treckmann JW; Hoyer DP
    Ann Transplant; 2019 May; 24():242-251. PubMed ID: 31048668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disadvantage of Small (<60 kg) Adult Candidates on the Liver Transplantation Waitlist.
    van Dijk ARM; Sneiders D; Murad SD; Polak WG; Hartog H
    Prog Transplant; 2020 Dec; 30(4):349-354. PubMed ID: 32912082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in Characteristics of Patients Listed for Liver Transplantation Will Lead to Higher Rates of Waitlist Removal Due to Clinical Deterioration.
    Yi Z; Mayorga ME; Orman ES; Wheeler SB; Hayashi PH; Barritt AS
    Transplantation; 2017 Oct; 101(10):2368-2374. PubMed ID: 28858174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inequity in organ allocation for patients awaiting liver transplantation: Rationale for uncapping the model for end-stage liver disease.
    Nadim MK; DiNorcia J; Ji L; Groshen S; Levitsky J; Sung RS; Kim WR; Andreoni K; Mulligan D; Genyk YS
    J Hepatol; 2017 Sep; 67(3):517-525. PubMed ID: 28483678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes for liver transplant candidates listed with low model for end-stage liver disease score.
    Kwong AJ; Lai JC; Dodge JL; Roberts JP
    Liver Transpl; 2015 Nov; 21(11):1403-9. PubMed ID: 26289624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Waitlist Outcomes in Liver Transplant Candidates with High MELD and Severe Hepatic Encephalopathy.
    Gadiparthi C; Cholankeril G; Yoo ER; Hu M; Wong RJ; Ahmed A
    Dig Dis Sci; 2018 Jun; 63(6):1647-1653. PubMed ID: 29611079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethnic and Age Disparities in Outcomes Among Liver Transplant Waitlist Candidates.
    Mustian MN; Shelton BA; MacLennan PA; Reed RD; White JA; Eckhoff DE; Locke JE; Allman RM; Gray SH
    Transplantation; 2019 Jul; 103(7):1425-1432. PubMed ID: 30418427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revising model for end-stage liver disease from calendar-time cross-sections with correction for selection bias.
    de Ferrante HC; van Rosmalen M; Smeulders BML; Vogelaar S; Spieksma FCR
    BMC Med Res Methodol; 2024 Feb; 24(1):51. PubMed ID: 38419019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Liver Offers to Pediatric Candidates on the Transplant Wait List.
    Hsu EK; Shaffer ML; Gao L; Sonnenday C; Volk ML; Bucuvalas J; Lai JC
    Gastroenterology; 2017 Oct; 153(4):988-995. PubMed ID: 28711630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk.
    Somsouk M; Kornfield R; Vittinghoff E; Inadomi JM; Biggins SW
    Liver Transpl; 2011 Feb; 17(2):129-36. PubMed ID: 21280185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.
    Nagai S; Kitajima T; Yeddula S; Salgia R; Schilke R; Abouljoud MS; Moonka D
    Hepatology; 2020 Dec; 72(6):2051-2062. PubMed ID: 32157711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality.
    Abdallah MA; Kuo YF; Asrani S; Wong RJ; Ahmed A; Kwo P; Terrault N; Kamath PS; Jalan R; Singal AK
    J Hepatol; 2021 Jun; 74(6):1355-1361. PubMed ID: 33326814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do Social Determinants Define "Too Sick" to Transplant in Patients With End-stage Liver Disease?
    Bababekov YJ; Hung YC; Chang DC; Rickert CG; Adler JT; Bethea E; Pomfret EA; Pomposelli JJ; Yeh H
    Transplantation; 2020 Feb; 104(2):280-284. PubMed ID: 31335769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should All Status 1A Patients Be Prioritized Over High MELD Patients? Concept of Risk Stratification in Extremely Ill Liver Transplant Recipients.
    Safwan M; Nwagu U; Collins K; Abouljoud M; Nagai S
    Transplantation; 2019 Oct; 103(10):2121-2129. PubMed ID: 30747840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refitting the Model for End-Stage Liver Disease for the Eurotransplant Region.
    Goudsmit BFJ; Putter H; Tushuizen ME; Vogelaar S; Pirenne J; Alwayn IPJ; van Hoek B; Braat AE
    Hepatology; 2021 Jul; 74(1):351-363. PubMed ID: 33301607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wait-list mortality of young patients with Biliary atresia: Competing risk analysis of a eurotransplant registry-based cohort.
    van der Doef HPJ; van Rheenen PF; van Rosmalen M; Rogiers X; Verkade HJ;
    Liver Transpl; 2018 Jun; 24(6):810-819. PubMed ID: 29377411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The decreasing predictive power of MELD in an era of changing etiology of liver disease.
    Godfrey EL; Malik TH; Lai JC; Mindikoglu AL; Galván NTN; Cotton RT; O'Mahony CA; Goss JA; Rana A
    Am J Transplant; 2019 Dec; 19(12):3299-3307. PubMed ID: 31394020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High risk of delisting or death in liver transplant candidates following infections: Results from the North American Consortium for the Study of End-Stage Liver Disease.
    Reddy KR; O'Leary JG; Kamath PS; Fallon MB; Biggins SW; Wong F; Patton HM; Garcia-Tsao G; Subramanian RM; Thacker LR; Bajaj JS;
    Liver Transpl; 2015 Jul; 21(7):881-8. PubMed ID: 25845966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of MELD 30-allocation policy on liver transplant outcomes in Italy.
    Ravaioli M; Lai Q; Sessa M; Ghinolfi D; Fallani G; Patrono D; Di Sandro S; Avolio A; Odaldi F; Bronzoni J; Tandoi F; De Carlis R; Pascale MM; Mennini G; Germinario G; Rossi M; Agnes S; De Carlis L; Cescon M; Romagnoli R; De Simone P
    J Hepatol; 2022 Mar; 76(3):619-627. PubMed ID: 34774638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.